Trial to reduce radiation fields in p16+ oropharyngeal cancer
Part of Cancer clinical trials.
This study tests whether shrinking the “planned radiation area” (elective treatment volumes) can still treat p16-positive oropharyngeal cancer effectively. It may help reduce unnecessary radiation to nearby healthy tissues while keeping the cancer treatment curative.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign consent
- You have a p16-positive squamous cell cancer in the throat area (oropharynx: tonsil, soft palate, base of tongue, or nearby throat walls)
- Your cancer is at stage T1 to T3 and lymph node stage N1 to N2 (not N0 or N3, and not stage Ib node involvement)
- Your overall health allows cancer treatment: you can do most activities (ECOG 0–2) and blood and organ tests meet limits
- You have no prior head and neck cancer in the last 5 years and no prior head and neck radiation ever
- You must be able to complete the full radiation course and follow-up visits; you can’t be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan that may lower (de-escalate) therapy intensity for certain p16+ or HPV-positive throat cancers. It uses PET scan results and tumor features to try to keep cancer control while reducing side effects.
This Phase 2 study uses HPV test results from your tumor to safely lower (de-intensify) the strength of radiation for some HPV-positive oropharyngeal throat cancers. It aims to reduce side effects while keeping cancer control effective.
This Phase 2 study tests whether a more precisely targeted radiation plan to the neck can work for people with p16-positive oropharynx cancer that is considered “favorable risk.” Doctors use special imaging to map where lymph nodes are likely involved, aiming to treat the right areas while avoiding unnecessary treatment.
This Phase 2 study tests whether removing the tumor through the mouth, followed by a reduced course of radiation, can control HPV-related (p16+) oropharynx throat cancer. It may help reduce treatment intensity after surgery, while still aiming to keep the cancer from coming back.
This trial tests a less intense treatment approach for people with HPV-positive oropharyngeal cancer. It uses surgery first, followed by fewer or lower doses of radiation and chemotherapy, aiming to reduce side effects while keeping treatment effective.
This trial tests a lower dose of radiation to certain neck areas for people with HPV-related oropharyngeal cancer. The goal is to see if reducing radiation can cause fewer side effects while still curing the cancer.
Hear when a new Squamous Cell Carcinoma of the Oropharynx trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.